CarrieBrownsteinMD

PubMed

• 45 citations
  A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
  Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni Ryan Abdul Razak, Katherine Van Loon
  Clinical Cancer Research. 2016-03-15
• 97 citations
  Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages
  Carrie Brownstein, Arunkumar B. Deora, Andrew T. Jacovina, Rebecca Weintraub, Menard M. Gertler
  Blood. 2004-01-01
• 3 citations
  The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
  Sarah A. Holstein, Nizar J. Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli
  Transplantation and Cellular Therapy. 2021-10-01

Abstracts/Posters

• Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized...
  Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
  Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
  Carrie Brownstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
  Carrie Brownstein, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• Join now to see all